Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-08
2010-06-22
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07741286
ABSTRACT:
Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
REFERENCES:
patent: 4462941 (1984-07-01), Lee et al.
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5424286 (1995-06-01), Eng
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5733876 (1998-03-01), O'Reilly et al.
patent: 5776704 (1998-07-01), O'Reilly et al.
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: 5801146 (1998-09-01), Davidson
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5840733 (1998-11-01), Krantz et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5854221 (1998-12-01), Cao et al.
patent: 5864372 (1999-01-01), Chen et al.
patent: 5885795 (1999-03-01), O'Reilly et al.
patent: 5942620 (1999-08-01), Krantz et al.
patent: 5945403 (1999-08-01), Folkman et al.
patent: 5972896 (1999-10-01), Davidson
patent: 5981484 (1999-11-01), Davidson
patent: 6024688 (2000-02-01), Folkman et al.
patent: 6057122 (2000-05-01), Davidson
patent: 6087375 (2000-07-01), Bridon et al.
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6277583 (2001-08-01), Krantz et al.
patent: 6277863 (2001-08-01), Krantz et al.
patent: 6284725 (2001-09-01), Coolidge et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6403324 (2002-06-01), Krantz et al.
patent: 6437092 (2002-08-01), Ezrin et al.
patent: 6440417 (2002-08-01), Thibaudeau et al.
patent: 6451974 (2002-09-01), Hansen
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 6514500 (2003-02-01), Bridon et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6602981 (2003-08-01), Ezrin et al.
patent: 6610825 (2003-08-01), Ezrin et al.
patent: 6706892 (2004-03-01), Ezrin et al.
patent: 6723530 (2004-04-01), Drucker
patent: 6767887 (2004-07-01), Hoffmann et al.
patent: 6821949 (2004-11-01), Bridon et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 6887470 (2005-05-01), Bridon et al.
patent: 6887849 (2005-05-01), Bridon et al.
patent: 7090851 (2006-08-01), Bridon et al.
patent: 7112567 (2006-09-01), Bridon et al.
patent: 7144854 (2006-12-01), Bridon et al.
patent: 7166695 (2007-01-01), Krantz et al.
patent: 7256253 (2007-08-01), Bridon et al.
patent: 7268113 (2007-09-01), Bridon et al.
patent: 7307148 (2007-12-01), Bousquet-Gagnon et al.
patent: 2003/0170250 (2003-09-01), Ezrin et al.
patent: 2004/0127398 (2004-07-01), Bridon et al.
patent: 2004/0138100 (2004-07-01), Bridon et al.
patent: 2004/0156859 (2004-08-01), Ezrin et al.
patent: 2004/0266673 (2004-12-01), Bakis et al.
patent: 2005/0065075 (2005-03-01), Erickson et al.
patent: 2005/0070475 (2005-03-01), Bridon et al.
patent: 2005/0176641 (2005-08-01), Bakis et al.
patent: 2005/0176643 (2005-08-01), Bridon et al.
patent: 2006/0058235 (2006-03-01), Bridon et al.
patent: 2006/0135426 (2006-06-01), Bridon et al.
patent: 2006/0135428 (2006-06-01), Bridon et al.
patent: 2006/0217304 (2006-09-01), Bridon et al.
patent: 2006/0241019 (2006-10-01), Bridon et al.
patent: 2007/0207958 (2007-09-01), Bridon et al.
patent: 2007/0269863 (2007-11-01), Bridon et al.
patent: 0602290 (1994-06-01), None
patent: WO 91/08220 (1991-06-01), None
patent: WO-95/10302 (1995-04-01), None
patent: WO 97/25074 (1997-01-01), None
patent: WO 97/29372 (1997-01-01), None
patent: WO-97/23500 (1997-07-01), None
patent: WO-97/41284 (1997-11-01), None
patent: WO-97/41824 (1997-11-01), None
patent: WO 9741824 (1997-11-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/00171 (1998-01-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/11437 (1998-03-01), None
patent: WO 99/24076 (1998-11-01), None
patent: WO-98/54217 (1998-12-01), None
patent: WO-99/00420 (1999-01-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/24071 (1999-05-01), None
patent: WO-99/24074 (1999-05-01), None
patent: WO-99/24075 (1999-05-01), None
patent: WO 99/24462 (1999-05-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/46283 (1999-05-01), None
patent: WO-99/48536 (1999-09-01), None
patent: WO-00/04052 (2000-01-01), None
patent: WO-00/13576 (2000-03-01), None
patent: WO 00/69902 (2000-05-01), None
patent: WO-00/47729 (2000-08-01), None
patent: WO-00/48595 (2000-08-01), None
patent: WO-00/54796 (2000-09-01), None
patent: WO-00/61179 (2000-10-01), None
patent: WO-00/69900 (2000-11-01), None
patent: WO 00/69911 (2000-11-01), None
patent: WO 01/17568 (2001-03-01), None
patent: WO 01/17614 (2001-03-01), None
patent: WO 02/62844 (2002-01-01), None
patent: WO 02/66511 (2002-02-01), None
patent: WO 02/96935 (2002-05-01), None
patent: WO 2004/011498 (2004-02-01), None
patent: WO 2005/012346 (2005-02-01), None
patent: WO 2005/103087 (2005-04-01), None
patent: WO 2005/108418 (2005-06-01), None
patent: WO 2007/053946 (2007-05-01), None
patent: WO 2007/071068 (2007-06-01), None
Peeters et al. (J. Immunol Methods 1989; 120: 133-143).
Narazaki et al .(Pharmaceutical Research 1997; 14: 351-353).
Bridon, et al., U.S. Appl. No. 09/623,543, filed Sep. 5, 2000.
Anti-Cancer Drugs, 1997, 8, 677-685.
Bailey, P.D., (1990)An Introduction to Peptide Chemistry, John Wiley & Sons, Inc., New York, NY, pp. 132-133.
Cancer Research, 1986, 46, 467-473.
Dermer, Gerard B., (Mar. 1994) “Another Anniversary for the War on Cancer,” Bio/Technology, 12: 320.
Humphries, Martin J. et al., (1994) “Conjugation of synthetic peptides to carrier proteins for cell adhesion studies,” J. Tissue Culture Methods, 16: 239-242.
J. Natl. Cancer Institute, 1989, 82, 4-6.
Peeters, J. M. et al., (1989) “Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates,” J. Immunol. Methods, 120:133-143.
Pietersz, Geoffrey A., (1990) “The Linkage of Cytotoxic Drugs to Monoclonal Antibodies for the Treatment of Cancer,” Bioconjugate Chemistry, 1(2):89-94.
Yeh, Patrice et al., (Mar. 1992) “Design of yeast-secreted albumin derivatives for human therapy: Biological and antiviral properties of serum albumin-CD4 genetic conjugate,” Proc. Natl. Acad. Sci. USA, 89: 1904-1908.
U.S. Appl. No. 60/037,412, filed Feb. 5, 1997, Drucker.
U.S. Appl. No. 60/103,498, filed Oct. 8, 1998, Coolidge et al.
U.S. Appl. No. 60/132,018, filed Apr. 30, 1999, Prickett et al.
U.S. Appl. No. 60/152,681, filed Sep. 7, 1999, Ezrin et al.
U.S. Appl. No. 09/424,571, filed Nov. 22, 1999, Ezrin et al.
Alberts et al., 1994,Molecular Biology of the Cell, Third Edition. New York: Garland Publishing, p. G19.
Barragán et al., 1996, “Interactions of Exendin(9-39) with the Effects of Glucagon-Like Peptide-l-(7-36) Amide and of Exendin-4 on Arterial Blood Pressure and Heart Rate in Rats,” 67:63-68.
Binder et al., 1984, “Insulin Pharmacokinetics,”Diabetes Care7:188-199.
Breton et al., 1995, “Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin,”Eur. J. Biochem. 231:563-569.
Catalog, Shearwater Polymers, Inc., Functionalized Biocompatible Polymers for Research, Polyethylene Glycol Derivatives, 1993.
Cooper, 1997,The Cell A Molecular Approach, ASM Press (Washington, DC), Sinauer Associates, Inc. (Sunderland, MA), 296-298, 648.
Edwards et al., (Dec. 1998), “Glucagon-Like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans,”Diabetes48: 86-
Beliveau Richard
Bridon Dominique P.
Huang Xicai
Rasamoelisolo Michele
Thibaudeau Karen
ConjuChem Biotechnologies Inc.
Fetterolf Brandon J
Jones Day
LandOfFree
Long lasting anti-angiogenic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Long lasting anti-angiogenic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long lasting anti-angiogenic peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232431